conferenceseries.com

5th International Congress on PHYSICS

March 03, 2022 | Webinar

The Effectiveness of Copegus (Ribavirin) placed in a Field of Unexplored Properties of Low-Level Laser Radiation in the Treatment of Post-Covid syndrome

Naylya Djumaeva

Scientific-Research Institute of Virology, Uzbekistan

For more than a year, the whole world is shocked by a new infection that has claimed more than four and a half million lives worldwide. This preliminary study describes an application of un-explored properties of low-level laser radiation with laser- light emitter (Uzbekistan, 2005) in the field of which is placed a Copegus (Ribavirin) (Hoffmann-La Roche) with the aim of treatment of patients with Post-Covid syndrome. The difference from the traditional use of the drug is that Copegus was not prescribed to the patient by the traditional method - orally or intravenously, and the medicinal properties of the drug were introduced into the patient's body using the un-explored properties of low-power laser radiation Sixty patients with Post- Covid syndrome were observed. The obtained findings suggest that under the influence of field formed into the laser- light emitter with a Copegus placed inside the field, the remote transfer of pharmacological properties of Copegus occurs. Conclusions about the produced effect of exposure were made based on improvement in the condition of patients, disappearance of complaints and positive changes in various diagnostic tests performed by the patient.

Biography

Djumaeva N has completed her PhD at the age 40 years from Institute of Epidemiology, Microbiology and Infectious Diseases (Uzbekistan). In her dissertation work devoted to the treatment of patients with chronic hepatitis B virus infection, she presented data on the possible influence of Complex Homeopathic Preparations on the organization of bound intracellular water in the cells of the body. She is the Consultant (Neurologist) at the Scientific-Research Institute for Virology, Uzbekistan and an expert in "medicament testing" method (30 years). She has published 43 papers, including 2 patents.

naila.djumaeva@gmail.com